学习经历

2013-09 至 2019-07, 清华大学，生物专业, 博士

主要工作经历与任职情况

2019-09 至 2022-03, 美国哈佛医学院，博士后

2022-04 至 2024-04, 美国哥伦比亚大学，副研究员

2024-05 至 2025-04, 美国哥伦比亚大学，助理教授

2025-05 至 至今, 武汉大学生命科学学院教授、高致病性病毒与生物安全国家重点实验室教授、泰康生命医学中心教授

主要科研奖励和个人荣誉

2023年获国家自然科学基金优秀青年科学基金项目（海外）

2023年获湖北省百人计划

2023中国区“35岁以下科技创新35人”

主要研究领域及兴趣

王茜博士长期从事病毒进化、感染机制及人体体液免疫应答等相关研究。未来将重点围绕病毒变异传播的分子基础、免疫压力驱动下的抗原变异机制、病毒进化路径预测、以及群体免疫监测等方向开展工作，旨在揭示病毒长期演化与公共健康风险之间的内在联系。

承担课程

本科生：无

研究生：2名博士研究生和1名硕士研究生

主持课题项目

· 　武汉大学人才启动经费

· 　国家海外高层次人才项目

发表的论文（*第一作者，#通讯作者）

1. Wang Q*, Guo Y*, Casner RG*, Yu J, Nair MS, Ho J, Reddem ER, Tzang CC, Huang Y, Shapiro L, Liu L. Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2. Nature Communications 2025. Accepted in principle.
2. Wang Q*, Guo Y*, Ho J, Ho DD. Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages. New England Journal of Medicine 2024 Nov 14;391(19):1863-1864.
3. Wang Q*, Guo Y*, Mellis IA*, Wu M*, Mohri H, Gherasim C, Valdez R, Purpura LJ, Yin MT, Gordon A, Ho DD. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. Cell Reports. 2025 Apr 8;44(4):115543. doi: 10.1016/j.celrep.2025.115543.
4. Wang Q*, Mellis IA*, Wu M*, Bowen A*, Gherasim C, Valdez R, Shah JG, Purpura LJ, Yin MT, Gordon A, Guo Y, Ho DD. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. The Lancet Infectious Diseases 2025 Feb 4:S1473-3099(25)00058-1.
5. Wang Q*, Mellis IA*, Ho J*, Bowen A, Kowalski-Dobson T, Valdez R, Katsamba PS, Wu M, Lee C, Shapiro L, Gordon A, Guo Y, Ho DD, Liu L. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerging Microbes & Infections 2024 Sep 11:2402880.
6. Wang Q*, Mellis IA*, Guo Y*, Gherasim C, Valdez R, Gordon A, Ho DD, Liu L. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster. Cell Reports Medicine 2024 Aug 23:101701.
7. Wang Q*, Guo Y*, Bowen A*, Mellis IA*, Valdez R, Gherasim C, Gordon A, Liu L, Ho DD. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. Cell Host & Microbe 2024 Mar 13;32(3):315-321.e3.
8. Wang Q*, Guo Y*, Schwanz LT*, Mellis IA*, Sun Y, Qu Y, Urtecho G, Valdez R, Stoneman E, Gordon A, Wang HH, Ho DD, Liu L. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1. Emerging Microbes & Infections 2024 Dec;13(1):2359004.
9. Wang Q, Zhang S, Nguyen HT, Sodroski JG. Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells. Journal of Virology 2024 Feb 20;98(2):e0159423.
10. Wang Q*, Guo Y*, Liu L*, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L, Ho DD. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature 2023 Dec;624(7992):639-644.
11. Wang Q*, Guo Y*, Tam AR*, Valdez R, Gordon A, Liu L, Ho DD. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Reports Medicine 2023 Nov 21;4(11):101258.
12. Wang Q*, Bowen A*, Ho J*, Zhang RM*, Valdez R, Stoneman E, Gordon A, Liu L, Ho DD. SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster. Lancet 2023 Nov 18;402(10415):1827-1828.
13. Wang Q*, Guo Y*, Zhang RM*, Ho J*, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L, Ho DD. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. The Lancet Infectious Diseases 2023 Oct;23(10):e397-e398.
14. Wang Q*, Li Z*, Guo Y*, Mellis IA*, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A, Liu L, Ho DD. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. iScience 2023 Oct 18;26(11):108254.
15. Liu L*, Casner RA*, Guo Y*, Wang Q*, Iketani S*, Chan JFW*,Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L, Ho DD. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity 2023 Oct 10;56(10):2442-2455.e8.
16. Zhang Z*, Wang Q*, Nguyen HT, Smith AB, Sodroski JG. Alterations in gp120 Glycans or the gp41 Fusion Peptide-Proximal Region Modulate the Stability of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Pretriggered Conformation. Journal of Virology 2023 Sep 28;97(9):e0059223.
17. Wang Q*, Bowen A*, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A, Liu L, Ho DD. SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster. The Lancet Infectious Diseases 2023 May;23(5):527-528.
18. Wang Q*, Yeh AY*, Guo Y, Mohri H, Yu J, Ho DD, Liu L. Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2. Emerging Microbes & Infections 2023 May 3:2210237.
19. Wang Q*, Bowen A*, Valdez R, Gherasim C, Gordon A, Liu L, Ho DD. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. New England Journal of Medicine 2023 Feb 9;388(6):567-569.
20. Wang Q*, Iketani S*, Li Z*, Liu L*, Guo Y*, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 2023 Jan 19;186(2):279-286.e8.
21. Wang Q*, Li Z*, Ho J, Guo Y, Yeh AY, Liu M, Wang M, Yu J, Sheng Z, Huang Y, Liu L, Ho DD. Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization. The Lancet Infectious Diseases 2022 Oct 31:S1473-3099(22)00694-6.
22. Wang Q*, Iketani S*, Li Z, Guo Y, Yeh AY, Liu M, Yu J, Sheng Z, Huang Y, Liu L, Ho DD. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host & Microbe 2022 Sep 6:S1931-3128(22)00419-X.
23. Wang Q*, Guo Y*, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L, Ho DD. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022 Aug;608(7923):603-608.
24. Wang Q*^,#, Anang S*, Iketani S, Guo Y, Liu L, Katsamba PS, Shapiro L, Ho DD, Sodroski JG^#. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Reports 2022 Jun 14;39(11):110924.
25. Wang Q, Esnault F, Zhao M, Chiu TJ, Smith AB, Nguyen HT, Sodroski JG. Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can be Minimized by Distant State 1-Stabilizing Changes. Journal of Virology 2022 Mar 15;e0187821.
26. Wang Q*, Nair MS*, Anang S, Zhang S, Nguyen H, Huang Y, Liu L, Ho DD, Sodroski JG. Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. iScience 2021; Nov 19;24(11):103393.
27. Wang Q, Ma B, Liang Q, Zhu A, Wang H, Fu L, Han X, Shi X, Xiang Y, Shang H and Zhang L. Stabilized diverse HIV-1 envelope trimers for vaccine design. Emerging Microbes & Infections 2020 Dec;9(1):775-786.
28. Wang Q, Finzi A and Sodroski JG. The Conformational States of the HIV-1 Envelope Glycoproteins. Trends in Microbiology 2020 Aug;28(8):655-667.
29. Liu L*, Wang P*, Nair MS*, Yu J*, Rapp M*, Wang Q*, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020 Aug;584(7821):450-456.